Terns Pharmaceuticals: Valued As If It Can't Win
Source: SeekingAlpha
2025-09-30 06:52:21 ET
Thesis
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates with a focus on oncology and obesity....
Read the full article on Seeking Alpha
For further details see:
Terns Pharmaceuticals: Valued As If It Can't Win
Terns Pharmaceuticals Inc.
NASDAQ: TERN
TERN Trading
4.38% G/L:
$46.495 Last:
2,061,716 Volume:
$45.56 Open:
TERN Latest News
March 05, 2026 10:14:13 am
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
February 25, 2026 04:05:00 pm
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 20, 2026 12:22:22 am
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
February 17, 2026 12:52:00 pm
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
TERN Stock Data
$3,951,236,778
84,980,644
0.19%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
Foster City
